Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer
Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer
复制标题
聚乙二醇化脂质体阿霉素 (Doxil™) 治疗肾细胞癌的 II 期试验
作者：
K. Skubitz
12 名难治性肾细胞癌患者接受了聚乙二醇化脂质醛多柔比星 (Doxil™) 的 II 期研究。每个疗程的初始剂量为每四周 55 mg/m2，并根据粘膜炎和手足综合征（主要限制性毒性）调整剂量。毒性轻微，与之前的报告相似，但根据研究方案减少剂量是很常见的，该方案旨在控制皮肤和粘膜毒性。没有观察到明确的心脏毒性。 11 名可评估患者中未观察到客观反应。这项研究没有证明聚乙二醇化脂质体阿霉素对肾细胞癌的活性，尽管它可能具有轻微的毒性。
Twelve patients with refractory renal cell cancer weretreated on a phase II study of pegylated-liposomaldoxorubicin (Doxil™). The initial dose per course was55 mg/m2 every four weeks with dose modification based onmucositis and hand-foot syndrome (the main limitingtoxicities). Toxicities were mild and similar to previousreports but dose reduction per the study protocol, which wasdesigned to control the skin and mucosal toxicities, wascommon. No definite cardiac toxicity was observed. Noobjective responses were observed in 11 evaluable patients. This study did not demonstrate activity ofpegylated-liposomal doxorubicin in renal cell cancer,although it can be given with mild toxicity.
昼夜节律输注氟尿苷治疗进行性转移性肾细胞癌。
DOI：
10.1200/jco.1990.8.9.1504
发表时间：
1990
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Hrushesky,WJ;vonRoemeling,R;Lanning,RM;Rabatin,JT
通讯作者：
Rabatin,JT